Tagoor Laboratories has received a Drugs Controller General of India licence to manufacture favipiravir, the active pharmaceutical ingredient of an anti-viral drug approved for use in the treatment of mild-to-moderate Covid-19 cases.
The manufacturing facility located in West Godavari, Andhra Pradesh, has completed favipiravir development and is planning to enhance its production capabilities.
The DCGI earlier approved the use of favipiravir, an anti-viral drug used for treatment of influenza. The drug, developed in Japan, is a broad spectrum anti-viral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication.
P Kasi Viswanadha Raju, Managing Director, Tagoor Laboratories, in a statement said: “Tagoor Labs is capable of producing the drug without having to depend on any imports, as all the complex intermediates are developed in-house. The company is aiming to manufacture favipiravir in quantities sufficient to meet the growing domestic demand due to the pandemic.”
Tagoor Labs also